Pandemic printing: a novel 3D-printed swab for detecting SARS-CoV-2.
Adult
Betacoronavirus
/ isolation & purification
COVID-19
COVID-19 Testing
Clinical Laboratory Techniques
/ instrumentation
Coronavirus Infections
/ diagnosis
Diagnostic Techniques, Respiratory System
/ instrumentation
Female
Humans
Male
Middle Aged
Nasopharynx
/ virology
Pandemics
Patient Acceptance of Health Care
/ statistics & numerical data
Pneumonia, Viral
/ diagnosis
Printing, Three-Dimensional
SARS-CoV-2
COVID-19
Infectious diseases
Microbiology
Respiratory tract infections
Journal
The Medical journal of Australia
ISSN: 1326-5377
Titre abrégé: Med J Aust
Pays: Australia
ID NLM: 0400714
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
22
05
2020
accepted:
06
07
2020
pubmed:
11
8
2020
medline:
30
9
2020
entrez:
11
8
2020
Statut:
ppublish
Résumé
To design and evaluate 3D-printed nasal swabs for collection of samples for SARS-CoV-2 testing. An iterative design process was employed. Laboratory evaluation included in vitro assessment of mock nasopharyngeal samples spiked with two different concentrations of gamma-irradiated SARS-CoV-2. A prospective clinical study compared SARS-CoV-2 and human cellular material recovery by 3D-printed swabs and standard nasopharyngeal swabs. Royal Melbourne Hospital, May 2020. Participants in the clinical evaluation were 50 hospital staff members attending a COVID-19 screening clinic and two inpatients with laboratory-confirmed COVID-19. In the clinical evaluation, a flocked nasopharyngeal swab sample was collected with the Copan ESwab and a mid-nasal sample from the other nostril was collected with the 3D-printed swab. In the laboratory evaluation, qualitative agreement with regard to SARS-CoV-2 detection in mock samples collected with 3D-printed swabs and two standard swabs was complete. In the clinical evaluation, qualitative agreement with regard to RNase P detection (a surrogate measure of adequate collection of human cellular material) in samples collected from 50 hospital staff members with standard and 3D-printed swabs was complete. Qualitative agreement with regard to SARS-CoV-2 detection in three pairs of 3D-printed mid-nasal and standard swab samples from two inpatients with laboratory-confirmed SARS-CoV-2 was also complete. Using 3D-printed swabs to collect nasal samples for SARS-CoV-2 testing is feasible, acceptable to patients and health carers, and convenient.
Identifiants
pubmed: 32772375
doi: 10.5694/mja2.50726
pmc: PMC7436747
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
276-279Subventions
Organisme : NHMRC
ID : APP1174555
Pays : International
Organisme : NHMRC
ID : APP1105905
Pays : International
Organisme : NHMRC
ID : GNT1191321
Pays : International
Organisme : Medical Research Future Fund
ID : APP2002317
Pays : International
Informations de copyright
© 2020 AMPCo Pty Ltd.
Références
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
J Clin Microbiol. 2007 Sep;45(9):2902-8
pubmed: 17652480
Biomed Eng Online. 2016 Oct 21;15(1):115
pubmed: 27769304
J Travel Med. 2020 May 18;27(3):
pubmed: 32167146
JAMA. 2020 May 19;323(19):1981
pubmed: 32236503
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32295895
JAMA. 2020 Apr 14;323(14):1341-1342
pubmed: 32125371
Med J Aust. 2020 Jun;212(10):459-462
pubmed: 32237278
JAMA. 2020 Apr 21;323(15):1437-1438
pubmed: 32150622
J Clin Virol. 2020 Jul;128:104426
pubmed: 32417674
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32393482